Pascual-Gil, S. (Simón)

Filtering

2015 - 20182

Settings

Author search.filters.isAuthorOfPublication.68e06051-3634-4141-8e53-c9a09f47a136

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Nuevas estrategias para la reparación cardiaca basadas en sistemas de liberación poliméricos y factores de crecimiento
    (2018-10-31) Pascual-Gil, S. (Simón); Blanco-Prieto, M.J. (María José); Prosper-Cardoso, F. (Felipe); Prosper, F. (Felipe)
    Myocardial infarction (MI) is the main cardiovascular disease, causing more than 7 million deaths per year 1. In spite of its clinical relevance 2,3, this pathology is from been controlled and risk factors associated to it are considerably augmenting in modern society, as pointed out by the World Health Organization, which has estimated that the number of MI events will dramatically increase by 2030 1. MI is usually started by the occlusion of a coronary artery, that causes an ischemic condition in the cardiac tissue. This lack of oxygen supply induces a massive cell death of cardiac cells and a negative tissue remodeling takes place. Consequently, functional limitations and eventually death may occur.
  • Thumbnail Image
    Heart regeneration after miocardial infarction using synthetic biomaterials
    (Elsevier, 2015) Pascual-Gil, S. (Simón); Blanco-Prieto, M.J. (María José); Díaz-Herráez, P. (Paula); Garbayo, E; Prosper-Cardoso, F. (Felipe)
    Myocardial infarction causes almost 7.3 million deaths each year worldwide. However, current treatments are more palliative than curative. Presently, cell and protein therapies are considered the most promising alternative treatments. Clinical trials performed until now have demonstrated that these therapies are limited by protein short half‐life and by low transplanted cell survival rate, prompting the development of novel cell and protein delivery systems able to overcome such limitations. In this review we discuss the advances made in the last 10 years in the emerging field of cardiac repair using biomaterial‐based delivery systems with focus on the progress made on preclinical in vivo studies. Then, we focus in cardiac tissue engineering approaches, and how the incorporation of both cells and proteins together into biomaterials has opened new horizons in the myocardial infarction treatment. Finally, the ongoing challenges and the perspectives for future work in cardiac tissue engineering will also be discussed.